Mammary Development and Breast Cancer: a Notch Perspective

Weizhen Chen, Wei Wei, Liya E. Yu, Zi Ye, Fujing Huang, Liyan Zhang, Shiqi Hu, Cheguo CaiJournal of Mammary Gland Biology and Neoplasia 2021 · DOI

Abstract

Mammary gland development primarily occurs postnatally, and this unique process is complex and regulated by systemic hormones and local growth factors. The mammary gland is also a highly dynamic organ that undergoes profound changes at puberty and during the reproductive cycle. These changes are driven by mammary stem cells (MaSCs). Breast cancer is one of the most common causes of cancer-related death in women. Cancer stem cells (CSCs) play prominent roles in tumor initiation, drug resistance, tumor recurrence, and metastasis. The highly conserved Notch signaling pathway functions as a key regulator of the niche mediating mammary organogenesis and breast neoplasia. In this review, we discuss mechanisms by which Notch contributes to breast carcinoma pathology and suggest potentials for therapeutic targeting of Notch in breast cancer. In summary, we provide a comprehensive overview of Notch functions in regulating MaSCs, mammary development, and breast cancer.

Introduction

The mammary gland is a unique organ, with the majority of its development occurring postnatally. It undergoes dramatic remodeling during puberty, pregnancy, lactation, and involution. These processes are tightly regulated by a combination of systemic hormones and local signaling pathways. Among these, the Notch signaling pathway has emerged as a master regulator of cell fate and "stemness." However, the same mechanisms that allow for healthy tissue growth are frequently hijacked by malignant cells. Breast cancer remains a leading cause of mortality, largely due to Cancer Stem Cells (CSCs) that drive tumor initiation, therapy resistance, and metastasis. Understanding the nuanced role of Notch signaling is critical for developing targeted therapies that can disrupt these processes without causing systemic toxicity.

The Notch Signaling Pathway

Notch signaling is a highly conserved cell-to-cell communication mechanism. It involves interactions between Notch receptors (Notch1–4) on a signal-receiving cell and ligands (such as DLL1, DLL3, DLL4, JAG1, and JAG2) on an adjacent signal-sending cell.

Overview of the canonical Notch signaling pathway, illustrating ligand-receptor interaction and subsequent proteolytic cleavage by ADAM and γ-secretase to release the Notch Intracellular Domain (NICD).

Upon ligand binding, the Notch receptor undergoes sequential proteolytic cleavages, first by ADAM proteases and then by the $\gamma$-secretase complex. This releases the Notch Intracellular Domain (NICD), which translocates to the nucleus. There, it forms a transcriptional complex with CSL and MAML to activate target genes such as HEY, HES, and CyclinD1. This pathway is naturally regulated by inhibitors like NUMB, which is often downregulated in breast tumors, leading to aberrant Notch activation.

Notch in Mammary Gland Development

The role of Notch is highly context-dependent, varying across different stages of life. Research using genetic mouse models and lineage tracing has mapped specific Notch components to key developmental milestones.

Temporal regulation of mammary gland development by specific Notch receptors and ligands from the embryonic stage through involution.

In the embryo, Notch1 serves as a marker for unipotent stem cells. During puberty, DLL1 and Notch3 are critical for ductal elongation. The most complex phase occurs during pregnancy and lactation, where all four Notch receptors (Notch1–4) along with Elf5 are involved in alveolar formation and functional differentiation. Finally, the gland undergoes involution, returning to a state similar to the adult virgin gland, a process also influenced by Notch signaling.

Notch and Breast Cancer Pathology

In the context of malignancy, Notch signaling is often dysregulated. It plays a pivotal role in maintaining the CSC population, which is responsible for the aggressive nature of certain breast cancer subtypes.

  • Subtype Specificity: Notch mutations and overactivation are particularly prevalent in Triple-Negative Breast Cancer (TNBC), where they drive poor clinical outcomes.
  • Therapy Resistance: High expression of the ligand JAG1 or the receptor Notch1 is associated with resistance to HER2-targeted therapies like trastuzumab. Inhibiting Notch has shown promise in re-sensitizing these tumors to treatment.
  • Metastatic Context: Interestingly, Notch's role in metastasis is site-specific. While Notch3 promotes bone metastasis, it has been shown to inhibit lung metastasis by upregulating GATA3, highlighting the complexity of therapeutic intervention.

Therapeutic Targeting and Future Directions

Targeting the Notch pathway presents both significant opportunities and challenges. Early clinical trials focused on $\gamma$-secretase inhibitors (GSIs) like RO4929097, but many faced hurdles due to systemic toxicity, particularly in the gastrointestinal tract where Notch is vital for homeostasis.

Current research is shifting toward more precise interventions, such as monoclonal antibodies (mAbs) targeting specific ligands (e.g., DLL4) or receptors. These "fine-tuned" approaches aim to disrupt tumor-specific signaling or angiogenesis while sparing healthy tissues. Furthermore, understanding the crosstalk between Notch and other pathways (Wnt, ER, PR) will be essential for developing effective combination therapies that can overcome resistance and improve patient survival.

Conclusion

Notch signaling is a fundamental pillar of mammary biology, governing development from the embryo to the reproductive cycle. Its role in breast cancer as a driver of stemness and resistance makes it a high-priority therapeutic target. However, the pathway's complexity necessitates a precision medicine approach to safely and effectively halt tumor progression.

Summary updated

Abstract

Mammary gland development primarily occurs postnatally, and this unique process is complex and regulated by systemic hormones and local growth factors. The mammary gland is also a highly dynamic organ that undergoes profound changes at puberty and during the reproductive cycle. These changes are driven by mammary stem cells (MaSCs). Breast cancer is one of the most common causes of cancer-related death in women. Cancer stem cells (CSCs) play prominent roles in tumor initiation, drug resistance, tumor recurrence, and metastasis. The highly conserved Notch signaling pathway functions as a key regulator of the niche mediating mammary organogenesis and breast neoplasia. In this review, we discuss mechanisms by which Notch contributes to breast carcinoma pathology and suggest potentials for therapeutic targeting of Notch in breast cancer. In summary, we provide a comprehensive overview of Notch functions in regulating MaSCs, mammary development, and breast cancer.
BibTeX
@article{chen2021mammary,
  author = {Weizhen Chen and Wei Wei and Liya E. Yu and Zi Ye and Fujing Huang and Liyan Zhang and Shiqi Hu and Cheguo Cai},
  title = {{Mammary Development and Breast Cancer: a Notch Perspective}},
  journal = {Journal of Mammary Gland Biology and Neoplasia},
  year = {2021},
  doi = {10.1007/s10911-021-09496-1},
}
Figure